SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Shasun gains on receiving USFDA approval For Abacavir Tablets

01 Nov 2016 Evaluate

Strides Shasun is currently trading at Rs. 1061.80, up by 18.80 points or 1.80% from its previous closing of Rs. 1043.00 on the BSE.

The scrip opened at Rs. 1044.00 and has touched a high and low of Rs. 1069.00 and Rs. 1026.20 respectively. So far 33,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1412.45 on 23-Nov-2015 and a 52 week low of Rs. 848.00 on 29-Feb-2016.

Last one week high and low of the scrip stood at Rs. 1069.00 and Rs. 936.95 respectively. The current market cap of the company is Rs. 9,460.28 crore.

The promoters holding in the company stood at 31.14%, while Institutions and Non-Institutions held 47.91% and 20.95% respectively.

Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Abacavir Tablets USP, 300 mg. The US market for Abacavir is approximately $30 million according to IMS data. Abacavir Tablets is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.

The product will be manufactured at the company’s USFDA approved facility at Bangalore and marketed by Strides in the US Market. The product will be launched immediately.

Strides Shasun (formerly known as Strides Arcolab) is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.


Strides Pharma Scien Share Price

1101.55 8.30 (0.76%)
01-Jul-2026 13:11 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1871.80
Dr. Reddys Labs. 1346.55
Cipla 1456.85
Zydus Lifesciences 1110.30
Lupin 2400.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: